Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis

Journal of Biological Chemistry

Volumn 289, Issue 23, 2014, Pages 16508-16515

  Bhattacharya, Debapriya ^a   Dwivedi, Ved Prakash ^a   Maiga, Mamoudou ^b   Maiga, Mariama ^b   Van Kaer, Luc ^c   Bishai, William R ^b   Das, Gobardhan ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNE SYSTEM;

ALTERNATE METHOD; CELL RESPONSE; HOST IMMUNE RESPONSE; IMMUNE RESPONSE; M. TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; THERAPEUTIC AGENTS; THERAPEUTIC COMPOUNDS;

DRUG THERAPY;

4 [4 (2,3 DIHYDRO 1,4 BENZODIOXIN 6 YL) 5 (2 PYRIDINYL) 1H IMIDIAZOL 2 YL]BENZENE; D 4476; SUPLATAST TOSYLATE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; CONTROLLED STUDY; FEMALE; IMMUNE EVASION; IMMUNOTHERAPY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; TUBERCULOSIS;

IMMUNOLOGY; IMMUNOTHERAPY; INTERLEUKIN; MYCOBACTERIUM TUBERCULOSIS; T CELL;

ANIMALS; FLOW CYTOMETRY; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; TH1 CELLS; TH2 CELLS; TUBERCULOSIS;

EID: 84902197856     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.558098     Document Type: Article

References (41)

1. World Health Organization (2012) Global Tuberculosis Report 2012, Geneva, Switzerland
2. Chensue, S. W., Warmington, K., Ruth, J., Lincoln, P., Kuo, M. C., and Kunkel, S. L. (1994) Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor. Am. J. Pathol. 145, 1105-1113
3. Barnes, P. F., Bloch, A. B., Davidson, P. T., and Snider, D. E., Jr. (1991) Tuberculosis in patients with human immunodeficiency virus infection. N. Engl. J. Med. 324, 1644-1650
4. Snider, D. E., Jr., and Roper, W. L. (1992) The new tuberculosis. N. Engl. J. Med. 326, 703-705
5. Flynn, J. L., and Chan, J. (2001) Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93-129
6. Lienhardt, C, Azzurri, A., Amedei, A., Fielding, K., Sillah, J., Sow, O. Y., Bah, B., Benagiano, M., Diallo, A., Manetti, R., Manneh, K., Gustafson, P., Bennett, S., D'Elios, M. M., McAdam, K., and Del Prete, G. (2002) Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur. J. Immunol. 32, 1605-1613
7. Agger, E. M., and Andersen, P. (2001) Tuberculosis subunit vaccine development: on the role of interferon-7. Vaccine 19, 2298-2302
8. Demissie, A., Abebe, M., Aseffa, A., Rook, G., Fletcher, H., Zumla, A., Weldingh, K., Brock, I., and ersen, P., and Doherty, T. M. (2004) Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4A2. J. Immunol. 172, 6938-6943
9. Fenhalls, G., Wong, A., Bezuidenhout, J., van Helden, P., Bardin, P., and Lukey, P. T. (2000) In situ production of 7 interferon, interleukin-4, and tumor necrosis factor α mRNA in human lung tuberculous granulomas. Infect. Immun. 68, 2827-2836
10. Ordway, D. J., Martins, M. S., Costa, L. M., Freire, M. S., Arroz, M. J., Dockrell, H. M., and Ventura, F. A. (2005) [Increased IL-4 production in response to virulent Mycobacterium tuberculosis in tuberculosis patients with advanced disease]. Acta Med. Port. 18, 27-36
11. Seah, G. T., Scott, G. M., and Rook, G. A. (2000) Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J. Infect. Dis. 181, 385-389
12. Dlugovitzky, D., Bottasso, O., Dominino, J. C, Valentini, E., Hartopp, R., Singh, M., Stanford, C, and Stanford, J. (1999) Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respir. Med. 93, 557-562
13. Rook, G. A., Dheda, K., and Zumla, A. (2005) Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat. Rev. Immunol. 5, 661-667
14. Hernandez-Pando, R., Aguilar, D., Hernandez, M. L., Orozco, H, and Rook, G. (2004) Pulmonary tuberculosis in BALB/c mice with non-functional IL-4 genes: changes in the inflammatory effects of TNF-α and in the regulation of fibrosis. Eur. J. Immunol. 34, 174-183
15. Rook, G. A., and Hernandez-Pando, R. (1996) The pathogenesis of tuberculosis. Annu. Rev. Microbiol. 50, 259-284
16. Scott-Browne, J. P., Shafiani, S., Tucker-Heard, G., Ishida-Tsubota, K., Fontenot, J. D., Rudensky, A. Y., Bevan, M. J., and Urdahl, K. B. (2007) Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J. Exp. Med. 204, 2159-2169
17. Shafiani, S., Dinh, C, Ertelt, J. M., Moguche, A. O., Siddiqui, I., Smigiel, K. S., Sharma, P., Campbell, D. J., Way, S. S., and Urdahl, K. B. (2013) Pathogen-specific Treg cells expand early during Mycobacterium tuberculosis infection but are later eliminated in response to interleukin-12. Immunity 38, 1261-1270
18. + regulatory T cells is mediated by cell surface-bound transforming growth factor/α. J. Exp. Med. 194, 629-644
19. Peng, Y., Laouar, Y., Li, M. O., Green, E. A., and Flavell, R. A. (2004) TGF-α regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc. Natl. Acad. Sci. U. S. A. 101, 4572-4577
20. + regulatory T cells and their therapeutic potential. Annu. Rev. Med. 57, 381-402
21. Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C G., and Glimcher, L. H. (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100, 655-669
22. Elo, L. L., Järvenpää, H., Tuomela, S., Raghav, S., Ahlfors, H., Laurila, K., Gupta, B., Lund, R. J., Tahvanainen, J., Hawkins, R. D., Oresic, M., Lähdesmäki, H., Rasool, O., Rao, K. V., Aittokallio, T., and Lahesmaa, R. (2010) Genome-wide profiling of interleukin-4 and STAT6 transcription factor regulation of human Th2 cell programming. Immunity 32, 852-862
23. + regulatory T cells. J. Mol. Cell. Biol. 2, 30-36
24. + regulatory T cells. J. Exp. Med. 201, 1061-1067
25. Oertelt, S., Lian, Z. X., Cheng, C. M., Chuang, Y. H., Padgett, K. A., He, X. S., Ridgway, W. M., Ansari, A. A., Coppel, R. L., Li, M. O., Flavell, R. A., Kronenberg, M., Mackay, I. R., and Gershwin, M. E. (2006) Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-β receptor II dominant-negative mice. J. Immunol. 177, 1655-1660
26. Szabo, S. J., Sullivan, B. M., Stemmann, C, Satoskar, A. R., Sleckman, B. P., and Glimcher, L. H. (2002) Distinct effects of T-bet in TH1 lineage commitment and IFN-7 production in CD4 and CD8 T cells. Science 295, 338-342
27. Kurokawa, M., Kawazu, K., Asano, K., Fumio, K., Mita, A., and Adachi, M. (2001) Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo. Mediators Inflamm. 10, 333-337
28. Callahan, J. F., Burgess, J. L., Fornwald, J. A., Gaster, L. M., Harling, J. D., Harrington, F. P., Heer, J., Kwon, C, Lehr, R., Mathur, A., Olson, B. A., Weinstock, J., and Laping, N. J. (2002) Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5). J. Med. Chem. 45, 999-1001
29. Gorelik, L., and Flavell, R. A. (2000) Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12, 171-181
30. Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C, Roberts, A. B., Sporn, M. B., Ward, J. M., and Karlsson, S. (1993) Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. U. S. A. 90, 770-774
31. Walzl, G., Ronacher, K., Hanekom, W., Scriba, T. J., and Zumla, A. (2011) Immunological biomarkers of tuberculosis. Nat. Rev. Immunol. 11, 343-354
32. Sweeney, K. A., Dao, D. N., Goldberg, M. F., Hsu, T., Venkataswamy, M. M., Henao-Tamayo, M., Ordway, D., Sellers, R. S., Jain, P., Chen, B., Chen, M., Kim, J., Lukose, R., Chan, J., Orme, I. M., Porcelli, S. A., and Jacobs, W. R., Jr. (2011) A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat. Med. 17, 1261-1268
33. Rook, G. A., Hernandez-Pando, R., Dheda, K., and Teng Seah, G. (2004) IL-4 in tuberculosis: implications for vaccine design. Trends Immunol. 25, 483-488
34. Boussiotis, V. A., Tsai, E. Y., Yunis, E. J., Thim, S., Delgado, J. C, Dascher, C. C, Berezovskaya, A., Rousset, D., Reynes, J. M., and Goldfeld, A. E. (2000) IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J. Clin. Invest. 105, 1317-1325
35. Raghuvanshi, S., Sharma, P., Singh, S., Van Kaer, L., and Das, G. (2010) Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc. Natl. Acad. Sci. U. S. A. 107, 21653-21658
36. Toossi, Z., and Ellner, J. J. (1998) The role of TGF β in the pathogenesis of human tuberculosis. Clin. Immunol. Immunopathol. 87, 107-114
37. Jayaswal, S., Kamal, M. A., Dua, R., Gupta, S., Majumdar, T., Das, G., Kumar, D., and Rao, K. V. (2010) Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS Pathog. 6, e1000839
38. Roy, E., Brennan, J., Jolles, S., and Lowrie, D. B. (2008) Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infection. Tuberculosis 88, 197-202
39. Oda, N., Minoguchi, K., Yokoe, T., Hashimoto, T., Wada, K., Miyamoto, M., Tanaka, A., Kohno, Y., and Adachi, M. (1999) Effect of suplatast tosilate (IPD-1151T) on cytokine production by allergen-specific human Th1 and Th2 cell lines. Life Sci. 65, 763-770
40. Henneekes, H, and Asadullah, K. (2002) Strategies for targeting IL4 as a novel therapeutic approach for the treatment of atopic dematities. Curr. Med. Chem. Anti. Inflamm. Anti. Allergy. Agents 41-53
41. van der Werf, N., Redpath, S. A., Azuma, M., Yagita, H., and Taylor M. D. (2013) Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. PLoS Pathog. 9, e1003215